Cyclacel Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 12
- Market Cap
- -
- Website
- http://www.cyclacel.com
- Introduction
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT00999401
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
- First Posted Date
- 2009-04-22
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT00885963
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT00590187
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Vanderbilt U Medical Center, Nashville, Tennessee, United States
A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT00560716
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00476554
- Locations
- 🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States
🇺🇸Timothy Kuzel, M.D., Chicago, Illinois, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT00380653
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
- First Posted Date
- 2006-09-06
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Target Recruit Count
- 187
- Registration Number
- NCT00372073
- Locations
- 🇺🇸
Pasco Hernando Oncology, New Port Richey, Florida, United States
🇺🇸Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Pacific Coast Hematology Oncology Group, Fountain Valley, California, United States